Rubicon Research IPO GMP Today
As of today, the Rubicon Research IPO is commanding a strong premium of ₹110 in the grey market, reflecting solid investor sentiment and expectations of a robust listing.
Rubicon Research IPO Overview
The Rubicon Research IPO opened for subscription on October 9, 2025, and will close on October 13, 2025. Investors now have just one more day to apply for the issue. The company has set a price band of ₹461–₹485 per equity share.
The IPO comprises a Fresh Issue worth ₹500 crore and an Offer for Sale (OFS) aggregating up to ₹877.50 crore, totaling ₹1,377.50 crore. The shares will be listed on both BSE and NSE.
Rubicon Research IPO GMP (Grey Market Premium)
According to market observers, Rubicon Research shares are trading at a ₹110 premium in the grey market today. This indicates a potential listing price around ₹595, which implies a listing gain of nearly 23% over the upper price band.
The strong grey market activity is attributed to robust subscription figures and positive investor sentiment in the pharma sector.
Rubicon Research IPO Subscription Status (Day 3)
As of 11:15 AM on Day 3, the IPO received overwhelming demand:
-
Total Subscription: 7.16 times
-
Retail Investors: 10.66 times
-
Non-Institutional Investors (NII): 14.79 times
-
Qualified Institutional Buyers (QIB): 2.19 times
This impressive subscription highlights the confidence of investors in Rubicon Research’s growth prospects and business fundamentals.
Rubicon Research IPO Review and Analyst Recommendations
-
Arihant Capital: Subscribe
“At the upper price band of ₹485, the IPO is valued at a P/E of around 60x based on FY25 annualized EPS of ₹8.2. Given its strong fundamentals, we recommend a ‘Subscribe’ rating for long-term investors.” -
Kunvarji Finstock: Subscribe for Medium to Long Term
“Rubicon Research has built a niche in the US generics market with a strong R&D base. We recommend subscribing to this IPO for medium to long-term gains, while monitoring global trade policy developments.”
Rubicon Research IPO Important Dates
| Event | Date |
|---|---|
| IPO Opens | October 9, 2025 |
| IPO Closes | October 13, 2025 |
| Basis of Allotment | October 14, 2025 |
| Refunds & Demat Credit | October 15, 2025 |
| Listing Date (BSE/NSE) | October 16, 2025 |
About Rubicon Research Limited
Rubicon Research is a pharmaceutical company focused on the development and manufacture of specialized generic formulations. With a strong R&D-driven approach and presence in the US and global markets, the company has shown consistent financial growth and innovation in product development.
Disclaimer
This article is for educational and informational purposes only. The views expressed are those of analysts and research firms, not of this platform. Investors are advised to consult a certified financial advisor before investing.
